

## **SUMMARY OF INTERVIEW**

### Attendees, Date and Type of Interview

The interview was conducted on October 18, 2007 and attended by Examiner Lei Yao, Supervisory Patent Examiner Shanon Foley and Applicants' representatives Daniel Hart and Jerry Hefner.

### Identification of Claims Discussed

Independent claim 15 was discussed.

### Identification of Prior Art Discussed

No prior art was discussed.

### Proposed Amendments

Applicants' representative proposed amending the claims to replace "THAP1" with "SEQ ID NO: 3" and to replace "30%" with "95%."

### Principal Arguments and Other Matters

Applicants' representatives stated that independent claim 15 was described and enabled by the specification; however, offered to amend the claim in order to overcome the instant written description and enablement rejections. The Examiners agreed that the amended claim would be adequately described by the specification but asked Applicants to provide evidence by way of a declaration that contacting a chemokine with a chemokine-binding domain of SEQ ID NO: 3 would produce an inhibition of chemokine activity.

### Results of Interview

Applicants' representatives agreed to provide a declaration demonstrating the inhibition of chemokine activity.